Christopher J Coughlin Centene Corp (CNC) insider trading activity

Christopher J Coughlin is Director of CENTENE CORP. Currently has a direct ownership of 13,016 shares of CNC, which is worth approximately $473,522. The most recent transaction as insider was on Dec 31, 2025, when has been sold 729 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 13K

5.93% 3M change

91.41% 12M change

Total Value Held $473,522

CHRISTOPHER J COUGHLIN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 31 2025	BUY Grant, award, or other acquisition	-	729 Added 5.3%	13,016 Common Stock
Sep 30 2025	BUY Grant, award, or other acquisition	-	852 Added 6.48%	12,287 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	-	556 Added 4.64%	11,435 Common Stock
May 13 2025	BUY Grant, award, or other acquisition	-	3,579 Added 24.75%	10,879 Common Stock
Mar 31 2025	BUY Grant, award, or other acquisition	-	500 Added 6.41%	7,300 Common Stock
Dec 31 2024	BUY Grant, award, or other acquisition	-	497 Added 6.81%	6,800 Common Stock
Dec 16 2024	BUY Open market or private purchase	$594,400 $59.44 p/Share	10,000 Added 21.57%	36,357 Common Stock

Sep 30 2024	BUY Grant, award, or other acquisition	-	402 Added 1.5%	26,357 Common Stock
Jun 30 2024	BUY Grant, award, or other acquisition	-	452 Added 1.71%	25,955 Common Stock
May 14 2024	BUY Grant, award, or other acquisition	-	2,916 Added 10.26%	25,503 Common Stock
Mar 31 2024	BUY Grant, award, or other acquisition	-	388 Added 1.69%	22,587 Common Stock
Dec 31 2023	BUY Grant, award, or other acquisition	-	502 Added 2.21%	22,199 Common Stock
Sep 30 2023	BUY Grant, award, or other acquisition	-	544 Added 2.45%	21,696 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	-	543 Added 2.5%	21,152 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	2,947 Added 12.51%	20,608 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	-	510 Added 2.81%	17,661 Common Stock
Dec 31 2022	BUY Grant, award, or other acquisition	-	443 Added 2.52%	17,150 Common Stock
Sep 30 2022	BUY Grant, award, or other acquisition	-	405 Added 2.37%	16,707 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	-	436 Added 2.61%	16,301 Common Stock
Apr 29 2022	BUY Open market or private purchase	$976,440 $81.37 p/Share	12,000 Added 43.07%	15,864 Common Stock
Apr 26 2022	BUY Grant, award, or other acquisition	-	2,323 Added 37.55%	3,864 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	$36,171 $82.02 p/Share	441 Added 22.25%	1,541 Common Stock
Feb 07 2022	BUY Grant, award, or other acquisition	-	1,100 Added 50.0%	1,100 Common Stock

Also insider at

ALXN

ALEXION PHARMACEUTICALS, INC.

Director

KRTX

Karuna Therapeutics, Inc. Healthcare

PBH

Prestige Consumer Healthcare Inc. Healthcare

Director

CJC